Monoclonal Gammopathy of Undetermined Significance (MGUS)
Symptoms, Doctors, Treatments, Advances & More

Monoclonal Gammopathy of Undetermined Significance (MGUS) Overview

Save information for later
Sign Up

Learn About Monoclonal Gammopathy of Undetermined Significance (MGUS)

What is the definition of Monoclonal Gammopathy of Undetermined Significance (MGUS)?
Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop.
What are the alternative names for Monoclonal Gammopathy of Undetermined Significance (MGUS)?
  • Monoclonal gammopathy of undetermined significance
  • MGUS
Who are the top Monoclonal Gammopathy of Undetermined Significance (MGUS) Local Doctors?
Elizabeth K. O'donnell
Elite in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Elizabeth K. O'donnell
Internal Medicine | Oncology
Elite in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Elizabeth K. O'donnell
Internal Medicine | Oncology

Dana-Farber Brigham Cancer Center

75 Francis Street, 
Boston, MA 
617-632-6140
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elizabeth O'donnell is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. O'donnell is rated as an Elite provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Orchiectomy, and Bone Marrow Aspiration.

Demet G. Yasar
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Demet G. Yasar
Hematology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Demet G. Yasar
Hematology

Vince Lombardi Cancer Clinic

2845 Greenbrier Rd, Ste 250, 
Green Bay, WI 
920-288-4180
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Demet Yasar is a Hematologist in Green Bay, Wisconsin. Dr. Yasar is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Myelodysplastic Syndrome (MDS).

 
 
 
 
Learn about our expert tiers
Learn More
Daniel J. Frank
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Daniel J. Frank
Oncology | Hematology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Daniel J. Frank
Oncology | Hematology
430 Warrenville Road, Suite 300, 
Lisle, IL 
630-364-7850
Experience:
20+ years
Languages Spoken:
English, Spanish
See accepted insurances

Each patient is unique and therapy needs to be tailored to an individual's personal needs and goals. Dr. Frank is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Familial Colorectal Cancer, Anemia, Myelodysplastic Syndrome (MDS), and Monoclonal Gammopathy of Undetermined Significance (MGUS).

View All Doctors
What are the latest Monoclonal Gammopathy of Undetermined Significance (MGUS) Clinical Trials?
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma (ORIGIN Study)
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma (ORIGIN Study)
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Other, Procedure

Summary: The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, ge...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION-3) Study
A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION-3) Study
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Other, Dietary supplement
Study Phase: Not Applicable

Summary: The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substa...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center